4 Key Insights for Pharma and Healthcare from Davos 2024
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
Patrick is the managing editor of PharmaBoardroom
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
After transitioning from a fledgling biotech to a mature commercial-stage company on the back of its first approval, Zealand Pharma was hit with the challenges of commercialisation and the disappointing…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
See our Cookie Privacy Policy Here
